Literature DB >> 4190545

Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.

J R Mendell, W K Engel, T N Chase.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4190545     DOI： 10.1016/s0140-6736(70)91629-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

2.  L-dopa and amantadine hydrochloride in extra-pyramidal disorders.

Authors:  J D Parkes; R P Knill-Jones; P J Clements
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

3.  The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.

Authors:  A Neophytides; A N Lieberman; M Goldstein; G Gopinathan; M Leibowitz; J Bock; R Walker
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

4.  Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis.

Authors:  L E Claveria; G Curzon; M J Harrison; B D Kantamaneni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-06       Impact factor: 10.154

5.  Treatment of Parkinson's disease with L-dopa: a current appraisal.

Authors:  O Kofman
Journal:  Can Med Assoc J       Date:  1971-03-20       Impact factor: 8.262

6.  Progressive supranuclear palsy: a brief personalized history.

Authors:  R B Daroff
Journal:  Yale J Biol Med       Date:  1987 Mar-Apr
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.